InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Crystal Roger, Chief Executive Officer. Officer active across 3 companies, notably Opiant Pharmaceuticals, INC.. Aggregated, 13 filings have been recorded. Breakdown: 1 buy · 6 sells. Total volume traded: €245k. History available since 16 September 2021. The latest transaction was filed on 21 June 2023 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Crystal Roger
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
4,666 sharesCommon SharesSEC:0001193125-26-271164:0
13,671 shares0Common SharesSEC:0000899243-23-016423:0
37,438 shares@ US$20.0068.6% of flowCommon StockSEC:0001385508-23-000069:0
1,358 shares@ US$20.262.5% of flowCommon StockSEC:0001385508-23-000034:0
1,183 shares@ US$20.202.2% of flowCommon StockSEC:0001385508-23-000018:0
5,029 shares@ US$20.209.4% of flowCommon StockSEC:0001385508-23-000005:0
89,286 shares0Common SharesSEC:0000899243-22-028728:0
2,246 shares@ US$11.112.4% of flowCommon StockSEC:0001385508-22-000109:0
6,667 shares0Common StockSEC:0001385508-22-000103:0
1,995 shares@ US$26.154.9% of flowCommon StockSEC:0001385508-22-000025:0
1,058 shares@ US$30.493.0% of flowCommon StockSEC:0001385508-22-000020:0
40,000 shares0Common StockSEC:0001385508-22-000008:0
100 shares@ US$23.440.2% of flowCommon Stock par value $0.001SEC:0001385508-21-000134:0
Canonical exit: 15 Dec 2021 (T+90)
13 of 13 declarations
About Crystal Roger
CRYSTAL ROGER is Directeur Général. He has filed 13 disclosures in total. Across the 13 recent sampled filings, purchases amount to EUR 1992 and sales to EUR 944970, with the dominant transaction type shown as sale, over the period from 2021-09-16 to 2026-06-15. The recent filings concern Opiant Pharmaceuticals, INC., Mind Medicine (MindMed) Inc., and Definium Therapeutics, Inc.
